Susan E. Barrowcliffe is General Manager & Europe at Aimmune Therapeutics, Inc. (AIMT). They have made 10 open-market trades across 1 company since 2016, most recently 2018-11-19.
CIK 0001664251
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AIMT | 49,375 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2018-11-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AIMT | SELL | 2018-11-19 | 2018-11-21 | $30.04 | $1.2M | -6.7% | -5.2% | -4.1% |
| AIMT | SELL | 2018-01-02 | 2018-01-04 | $37.12 | $2.7M | +2.5% | -4.3% | -19.5% |
| AIMT | SELL | 2018-01-02 | 2018-01-04 | $37.14 | $4.7M | +2.5% | -4.3% | -19.5% |
| AIMT | SELL | 2017-09-25 | 2017-09-27 | $25.00 | $500K | +0.2% | +17.5% | +53.8% |
| AIMT | SELL | 2017-09-06 | 2017-09-07 | $22.00 | $334K | +2.4% | +12.2% | +55.7% |
| AIMT | SELL | 2017-09-05 | 2017-09-07 | $22.00 | $405K | +2.4% | +12.2% | +55.7% |
| AIMT | SELL · 10b5-1 | 2017-07-27 | 2017-07-31 | $22.00 | $11K | -11.8% | -2.4% | +37.2% |
| AIMT | SELL | 2017-07-21 | 2017-07-25 | $22.00 | $134K | -0.8% | -7.4% | +51.8% |
| AIMT | SELL | 2017-07-03 | 2017-07-06 | $20.26 | $304K | +4.5% | +1.6% | +26.7% |
| AIMT | SELL | 2016-11-11 | 2016-11-15 | $25.00 | $500K | -5.5% | -13.1% | -26.4% |
| AIMT | SELL | 2016-11-08 | 2016-11-10 | $20.00 | $300K | -0.1% | -9.6% | -25.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.